|Chief Executive Officer of AMPIO Pharmaceuticals points to upcoming clinical trial results and key milestones|
|By Staff and Wire Reports|
|Tuesday, 28 February 2012 06:39|
In an exclusive video interview, Michael Macaluso, the Founder and Chief Executive Officer of AMPIO Pharmaceuticals tells investors that if 2011 was the firm’s year to get their drug candidates into clinical trials, then 2012 will be the year to prove that they really work. “We expect very good results and believe they will be the stepping stone for this company,” explains Macaluso. “We hope to move into the future with a much higher valuation.”
During the interview, Macaluso reiterates and clarifies some previous guidance about several key milestones set to occur within the first half of this year and technically it appears that shares may be attempting to recover from their recent bottom level lows. Clinical trial results for one of the company’s flagship drugs are expected shortly.
Ampio's product pipeline includes new uses for approved drugs and new molecular entities ('NMEs') for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The company's product pipeline includes: Optina(TM) for diabetic retinopathy, Vasaloc(TM) for diabetic nephropathy, and Ampion(TM) for chronic inflammation.